A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants

2025-523301-15-00 · tracked via the Priya Life Science EU tracker

Sponsor

Bayer AG

Sponsor type

Pharmaceutical company

Therapeutic area

Cardiovascular Diseases

Decision date

11/11/2025

Enrollment target

190

Sites

Germany

Condition studied

Vasodilatory shock

Eligibility

Age group

18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523301-15-00 on CTIS ↗ ← All trials in the EU

A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants

Condition studied

Eligibility

A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants